A Phase 4 interventional study of rosiglitazone and physical exercise in Impaired Glucose Tolerance, sponsored by University of Leipzig. Completed. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-02.
Sponsored by University of Leipzig · Phase 4, Interventional, and Treatment
The aim of this study is to prospectively assess the relative benefits of either treatment with rosiglitazone or physical exercise on endothelial function in patients with impaired fasting glucose or impaired glucose tolerance and coronary artery disease (CAD).
999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.
This study's enrollment of 45 is below the median of 65 across 844 interventional studies indexed under Prediabetic State.
Browse Prediabetic State studies →University of Leipzig is the lead sponsor of 147 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: rosiglitazone
physical exercise
Behavioral: physical exercise
control
Other: control
tablets 4 mg daily
Also known as: Avandia (GlaxoSmithKline)
stationary bike 5-6 times a week
control without intervention
between-group difference in flow-mediated dilation of the brachial artery
Time frame: 6 months
relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies
Time frame: 6 months
No study locations are listed for this record.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Leipzig